Evaluation of promiR-29 treatment regimen to prevent hypertrophic scarring

Project: Research project

Project Details


The objective of this project is to investigate the efficacy of promiR-29 as a new pharmacologic agent to prevent hypertrophic scarring after cutaneous injury. Our hypothesis is that administration of miR-29 following wound re-epithelialization will prevent the deposition or accumulation of collagen and other extracellular matrix proteins and thereby prevent scarring. miR-29 may therefore improve patient outcomes following trauma, burns or surgery, without compromising the ability to achieve wound closure.
Effective start/end date10/15/149/16/16


  • miRagen Therapeutics, Inc. (-)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.